Third-generation versus first-generation EGFR tyrosine kinase inhibitors in Asian patients with advanced EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled trials
Compared with FGETs, TGETs significantly improve PFS, CNS control, response outcomes, and maintain a comparable safety profile for Asian patients with advanced EGFR-mutated NSCLC.
Authors
- Mengwei Xu
- Linlin Wan (ORCID: https://orcid.org/0000-0002-3192-309X)
- Wei Ding (ORCID: https://orcid.org/0000-0003-4368-8215)
- Wenxiong Zhang (ORCID: https://orcid.org/0000-0003-2962-0847)
Institutions
- Nanchang University (CN)
- Second Affiliated Hospital of Nanchang University (CN)
- Xinyu University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-10-21
- DOI
- https://doi.org/10.1007/s12672-025-03767-7
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00